Results 91 to 100 of about 22,815 (201)

Economic evidence for licensed ready‐to‐administer intravenous products compared with standard vials and ampoules: a systematic review

Anaesthesia, EarlyView.
Summary Introduction Injectable medicines represent a significant proportion of the annual medicines expenditure of the NHS in England, totalling £7 billion ($9.4 billion, €8.0 billion) in 2023. This represents approximately 70% of hospital medicines spending and includes essential treatments delivered at the point of care, such as chemotherapy ...
Suzanne Al‐Rawi, Matthew Greening, Sue Ladds   +2 more
wiley   +1 more source

A simulation tool for better management of retinal services [PDF]

, 2018
Background: Advances in the management of retinal diseases have been fast-paced as new treatments become available, resulting in increasing numbers of patients receiving treatment in hospital retinal services.
A Kotecha, A Kotecha, Aimee Verner, Andriy Danyliv, CG Owen, David Southern, Eren Demir, FG Holz, GA Lalwani, HR Wright, JA Haller, K Hatz, Karsten Kortuem, Katja Hatz, KT Tsaousis, Line Kvannli, OP Gupta, RB Rush, S Trikha, W Amoaku, Winfried Amoaku   +20 more
core   +2 more sources

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem, Esra Inci, Martin Breimer, Sofia Töyrä Silfverswärd, Madeleine Zetterberg, Marita Andersson Grönlund   +5 more
wiley   +1 more source

Laser flare photometry: a cost-effective method for early detection of endophthalmitis after intravitreal injection of anti-VEGF agents

Journal of Ophthalmic Inflammation and Infection, 2018
Background Intravitreal injection of anti-vascular endothelial growth factor agents is the most common intraocular procedure worldwide, inevitably causing more cases of post-injection endophthalmitis. The purpose of this study was to evaluate the utility
Vânia Lages, Béatrice Gehrig, Carl P. Herbort   +2 more
doaj   +1 more source

Neovascular age‐related macular degeneration without drusen

Acta Ophthalmologica, EarlyView.
Abstract Purpose To describe the clinical characteristics and 1‐year follow‐up of patients with neovascular AMD (nAMD) without drusen in either eye. Methods This is a multicentre retrospective cohort study in three tertiary referral centres in The Netherlands. We included patients of 55 years or older with nAMD in one or both eyes, without the presence
Marc J. Sirks, Elon H. C. van Dijk, Husein Ghalayini, Somayeh Bazdar, WeiFeng Yu, Suzanne Yzer, José P. Martinez Ciriano, Reinier O. Schlingemann, Roselie M. H. Diederen, Camiel J. F. Boon   +9 more
wiley   +1 more source

The prechoroidal cleft in neovascular age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract The prechoroidal cleft is a lenticular, hypo‐reflective space on optical coherence tomography imaging, located between a band of fibrovascular material underneath the retinal pigment epithelium (RPE) and Bruch's membrane. It occurs in 8%–22% of neovascular age‐related macular degeneration (nAMD) eyes, most often with macular neovascularization
Niels J. Brouwer, T. H. Khanh Vu, Yvonne De Jong‐Hesse, Elon H. C. van Dijk   +3 more
wiley   +1 more source

Sustained gene expression in the retina by improved episomal vectors [PDF]

, 2014
Gene and cellular therapies are nowadays part of therapeutic strategies for the treatment of diverse pathologies. The drawbacks associated with gene therapy-low levels of transgene expression, vector loss during mitosis, and gene silencing-need to be ...
Ana V. Oliveira, Conley S.M., Davis A.A., Gabriela A. Silva, Reinisalo M., Rudolf Haase, Sofia M. Calado, Susana Machado   +7 more
core   +1 more source

Vitreoretinal complications and surgical outcomes in patients with X‐linked retinoschisis

Acta Ophthalmologica, EarlyView.
Abstract Purpose X‐linked retinoschisis (XLRS) is an inherited vitreoretinal disorder characterized by macular retinoschisis. In a subgroup of patients, peripheral retinoschisis can occur, potentially leading to complications such as vitreous haemorrhage (VH) and retinal detachment (RD).
Jonathan Hensman, Leo C. Hahn, Mary J. van Schooneveld, Roselie M. H. Diederen, Filip van den Broeck, Jacoline B. Ten Brink, Alberta A. Thiadens, Maria M. van Genderen, L. Ingeborgh van den Born, Bart P. Leroy, Carel B. Hoyng, Camiel J. F. Boon   +11 more
wiley   +1 more source

Intravitreal bevacizumab as therapy for refractory neovascular glaucoma secondary to iris metastasis of breast carcinoma

American Journal of Ophthalmology Case Reports, 2018
Purpose: To report a case of refractory glaucoma secondary to iris metastasis from breast cancer which was successfully treated with intravitreal bevacizumab.
Stephanie Vale, Lorena Montalvo, Emilio Baez, Armando L. Oliver   +3 more
doaj   +1 more source

Long‐term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate long‐term outcomes of anti‐VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry. Methods The cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow‐up through 31 October 2023. Long‐term follow‐up (>5 years) was conducted for 7631 eyes.
Sławomir Teper, Daniel Ledwoń, Adam Sendecki, Patrycja Romaniszyn‐Kania, Aleksandra Tuszy, Julia Nycz, Andrzej W. Mitas, Małgorzata Figurska, Edward Wylęgała, Marek Rękas   +9 more
wiley   +1 more source